Positive News SentimentPositive NewsNASDAQ:CV CapsoVision (CV) Stock Price, News & Analysis $6.70 +0.37 (+5.85%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$6.88 +0.18 (+2.69%) As of 09/18/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About CapsoVision Stock (NASDAQ:CV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CapsoVision alerts:Sign Up Key Stats Today's Range$6.26▼$6.7550-Day Range$5.82▼$7.1752-Week Range$4.34▼$15.37Volume1.61 million shsAverage Volume140,793 shsMarket Capitalization$335.34 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingHold Company Overview CapsoVision, Inc. is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure. The company’s principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract. The system is designed to provide broad visual coverage of the small bowel and support the detection and evaluation of abnormalities such as bleeding, lesions and other sources of disease. CapsoVision also offers software and cloud-based tools intended to support the storage, review and interpretation of capsule endoscopy images. Its solutions are marketed to healthcare providers and are available in the United States and selected international markets, subject to applicable regulatory clearances and approvals.AI Generated. May Contain Errors. Read More CapsoVision Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCV MarketRank™: CapsoVision scored higher than 70% of companies evaluated by MarketBeat, and ranked 200th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingCapsoVision has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCapsoVision has a consensus price target of $9.50, representing about 41.8% upside from its current price of $6.70.Amount of Analyst CoverageCapsoVision has only been the subject of 4 research reports in the past 90 days.Read more about CapsoVision's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CapsoVision are expected to grow in the coming year, from ($0.56) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CapsoVision is -14.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CapsoVision is -14.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapsoVision has a P/B Ratio of 23.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.85% of the float of CapsoVision has been sold short.Short Interest Ratio / Days to CoverCapsoVision has a short interest ratio ("days to cover") of 23.03, which indicates bearish sentiment.Change versus previous monthShort interest in CapsoVision has recently increased by 5.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapsoVision does not currently pay a dividend.Dividend GrowthCapsoVision does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment1.70 News SentimentCapsoVision has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for CapsoVision this week, compared to 2 articles on an average week. Company Ownership3.7 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of CapsoVision in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $6,007,899.00 in company stock, which represents 1.7916% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, CapsoVision insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,007,899.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.30% of the stock of CapsoVision is held by insiders.Percentage Held by InstitutionsCapsoVision has minimal institutional ownership at this time.Read more about CapsoVision's insider trading history. Receive CV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CapsoVision and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CV Stock News HeadlinesInsider Buying: CapsoVision (NASDAQ:CV) Major Shareholder Buys $4,999,996.46 in StockSeptember 19 at 6:37 AM | insidertrades.comMajor Investor Makes Bold Move on CapsoVision, Inc. SharesSeptember 18 at 10:11 PM | tipranks.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 20 at 1:00 AM | Behind the Markets (Ad)CapsoVision Announces $18 Million Direct Stock OfferingSeptember 18 at 4:51 PM | tipranks.comCapsoVision Announces Upcoming Investor Conference Participation for September 2026September 3, 2026 | quiverquant.comQCapsoVision to Participate in Upcoming Investor ConferencesSeptember 3, 2026 | globenewswire.comCapsoVision Earnings Call: Growth, AI Push, Margin StrainAugust 14, 2026 | tipranks.comCapsoVision anticipates FDA clearance for AI Highlights by end of Q3 as it targets Q4 CapsoCam Colon submissionAugust 13, 2026 | seekingalpha.comSee More Headlines CV Stock Analysis - Frequently Asked Questions How have CV shares performed this year? CapsoVision's stock was trading at $10.69 on January 1st, 2026. Since then, CV shares have decreased by 37.3% and is now trading at $6.70. How were CapsoVision's earnings last quarter? CapsoVision, Inc. (NASDAQ:CV) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $3.64 million for the quarter. CapsoVision had a negative net margin of 214.74% and a negative trailing twelve-month return on equity of 177.85%. Read the conference call transcript. When did CapsoVision IPO? CapsoVision (CV) raised $28 million in an initial public offering (IPO) on Wednesday, July 2nd 2025. The company issued 5,300,000 shares at $5.00-$5.50 per share. The Benchmark Company and Roth Capital Partners served as the underwriters for the IPO. Who are CapsoVision's major shareholders? CapsoVision's top institutional investors include BlackRock Inc. (3.80%), Bank of New York Mellon Corp (0.15%), Deutsche Bank AG (0.07%) and Bank of America Corp DE (0.05%). Insiders that own company stock include Eliyahou Et Al Harari and Ching Hang Shen. View institutional ownership trends. How do I buy shares of CapsoVision? Shares of CV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CV's financial health is in the Green zone, according to TradeSmith. CV has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:CV CIK1378325 Webcapsovision.com Phone(408) 370-4790FaxN/AEmployees99Year Founded2005Price Target and Rating Average Price Target for CapsoVision$9.50 High Price Target$10.00 Low Price Target$9.00 Potential Upside/Downside+41.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.32 million Net Margins-214.74% Pretax Margin-214.56% Return on Equity-177.85% Return on Assets-135.07% Debt Debt-to-Equity RatioN/A Current Ratio3.35 Quick Ratio2.44 Sales & Book Value Annual Sales$13.55 million Price / Sales24.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book23.93Miscellaneous Outstanding Shares50,050,000Free Float48,896,000Market Cap$335.34 million OptionableN/A Beta-2.47 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CV) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CapsoVision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CapsoVision With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
